CHF Solutions to Release Educational Webinar Highlighting Use of Aquadex FlexFlow® System in Post-Cardiovascular Surgery Featuring Noted Cardiovascular Surgeon, Daniel Beckles, MD, PhD
The 17-minute pre-recorded webinar is designed to provide a peer-to-peer overview of the issues associated with fluid overload in the post-cardiac surgery context. It is facilitated by
- Trends in adult cardiovascular surgery
- Complications resulting from cardiovascular surgery, including fluid overload
- The role of ultrafiltration in post-op cardiovascular patients
- Aquadex FlexFlow system and first-hand experience using the therapy following cardiac surgery
“Surgical patients can be challenged by fluid overload post-procedure due to the extra fluids administered during surgery or medications administered post-surgery. When these fluids are not removed, there is increased potential risk for morbidity, mortality, and readmissions,” commented
About CHF Solutions
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the benefits of the educational webinar, the potential of our expansion into the post-cardiovascular surgery market to be commercially successful and result in growth of the market for Aquadex Flex Flow and the ability of our expanded sales and marketing team to successfully implement the expansion to our commercial strategy. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with, and benefits from, acquired businesses, and other risks and uncertainties described in our filings with the
CONTACTS: INVESTORS:Claudia Napal Drayton Chief Financial OfficerCHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com -or-Bret Shapiro Managing Partner CORE IR 516-222-2560 brets@coreir.comwww.coreir.com MEDIAJules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com
Source: CHF Solutions, Inc.